In this phase II study, the overall response rate (ORR) and safety of rituximab and bortezomib was evaluated in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with MCL (n = 25) and 11 patients with FL were enrolled. The ORR in patients with FL was 55% and 29% in patients with MCL. Adverse events (AEs) were reported by 13 patients with the most common ones being sensory neuropathy, fatigue, neutropenia, neuropathy and constipation. No serious AEs were reported.

Read more here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.